PPTID is an uncommon tumour of the pineal gland that sits between the slow pineocytoma and the aggressive pineoblastoma. Most people need surgery, and some also need radiotherapy. Many do well, but long-term scans are important because it can return.
A pineal parenchymal tumour of intermediate differentiation (PPTID) is a rare brain tumour that starts in the cells of the pineal gland. This small gland lies near the centre of the brain and produces melatonin, the hormone that helps control the sleep-wake cycle. Its cells are called pinealocytes, and tumours that grow from them are called pineal parenchymal tumours.
The name “intermediate differentiation” describes how the tumour behaves. Its cells are more abnormal than those of a pineocytoma, a slow-growing grade 1 tumour, but less aggressive than those of a pineoblastoma, a fast-growing grade 4 tumour usually seen in children. PPTIDs are graded as WHO CNS grade 2 or 3, depending on how active the cells are under the microscope.
PPTID makes up less than 1% of all tumours that begin in the brain and spinal cord (Takase et al., 2022). It mostly affects adults, often in their 30s and 40s, but children and older people can also be affected. Most cause symptoms by blocking the flow of fluid around the brain, which leads to headaches and vomiting.
Laboratory research has shown that many PPTIDs carry small changes in a gene called KBTBD4. This finding helps pathologists tell PPTID apart from pineoblastoma (Lee et al., 2019).
Treatment usually starts with surgery to remove as much tumour as safely possible. Radiotherapy is often added, and chemotherapy may be used for higher-grade tumours. Because there are no large trials, treatment plans are tailored to each person by a specialist team.
1. Key facts at a glance
2. Types
The pineal parenchymal tumour family
Grade 2 versus grade 3 PPTID
A systematic review of 389 patients found that grading under the WHO classification was closely linked with survival (Takase et al., 2022). However, some tumours behave more aggressively than their grade suggests, which is why molecular tests are becoming more important.
Other tumours of the pineal region
3. Causes and risk factors
The cause of PPTID is not known.
PPTIDs typically lack the DROSHA deletions and DICER1 mutations found in many pineoblastomas (Lee et al., 2019). An international consensus study confirmed that PPTIDs form a distinct molecular group among pineal tumours (Liu et al., 2021).
4. How does it look
On scans
Under the microscope
5. Symptoms
Symptoms are caused mainly by raised pressure in the head and by pressure on the midbrain.
Common symptoms
- Headache, the most common symptom in one series, often worse in the morning (Webb et al., 2022)
- Nausea and vomiting
- Blurred or double vision
- Difficulty looking upwards (Parinaud syndrome)
- Unsteadiness when walking
Less common symptoms
When to seek urgent help
Get urgent medical help for a severe or worsening headache with vomiting, sudden visual change, drowsiness or confusion. These may signal dangerous pressure in the head.
6. Diagnosis
Managing hydrocephalus
Staging
PPTID is not staged like body cancers. Doctors record:
- The grade (2 or 3)
- Whether the tumour was fully removed
- Whether there is spread in the brain fluid or spine
7. Treatment
An international consensus from neuro-oncology societies notes that treatment of pineal tumours ranges from surgery alone to intensive combined therapy, depending on the tumour type and its features (Liu et al., 2024).
Surgery
Radiotherapy
The best type of radiotherapy remains uncertain. Whether radiotherapy to the whole brain and spine offers advantages over focal treatment is not clear (Webb et al., 2022).
Chemotherapy
For grade 3 and unusually aggressive tumours, a combination of maximal resection, radiotherapy and chemotherapy has been suggested as first-line treatment (Takase et al., 2022).
Treatment by situation
Recovery after pineal surgery
PPTID in children and older adults
PPTID is uncommon in children, and specialist paediatric teams plan treatment carefully to limit long-term effects of radiotherapy on growth, learning and hormones. In older adults, the team weighs the benefits of extensive surgery and radiotherapy against general health and other illnesses.
Side effects
8. Outlook (prognosis)
In a pooled analysis of 36 patients from three centres, 16 experienced recurrence and median overall survival was 44 months (Webb et al., 2022). In the Mayo Clinic group within that analysis, no deaths were reported during follow-up.
Recurrence and spread through the spinal fluid can occur many years after treatment, so long-term follow-up is important.
9. Follow-up
10. Living with PPTID
- Tell your team about new headaches, vision changes or back pain
- Use eye exercises or prisms if you have double vision; orthoptists can help
- Avoid driving until your doctor confirms it is safe and the licensing authority allows it
- Pace yourself; tiredness after treatment is common and can last months
- Ask for neuropsychology support if memory or concentration is affected
- Seek support from brain tumour charities and support groups
11. Frequently asked questions
12. Questions to ask your care team
- Is my tumour grade 2 or grade 3?
- Has molecular testing confirmed the diagnosis?
- Was the tumour completely removed?
- Has it spread to the spine or brain fluid?
- Do you recommend radiotherapy or chemotherapy?
- What side effects should I expect?
- How often will I need scans, and for how long?
- Is there a specialist nurse I can contact between appointments?
- Could I take part in a clinical trial?
Resources
- Lee, J.C. et al. (2019) ‘Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma’, Acta Neuropathologica, 137(5), pp. 851-854.
- Liu, A.P.Y. et al. (2021) ‘Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study’, Acta Neuropathologica, 141(5), pp. 771-785.
- Liu, A.P.Y. et al. (2024) ‘SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors’, Neuro-Oncology, 26(12), pp. 2159-2173.
- Takase, H. et al. (2022) ‘Pineal parenchymal tumor of intermediate differentiation: a systematic review and contemporary management of 389 cases reported during the last two decades’, Neurosurgical Review, 45(2), pp. 1135-1155.
- Webb, M. et al. (2022) ‘Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis’, Journal of Neuro-Oncology, 160(2), pp. 527-534.
- National Cancer Institute (2026) Adult Central Nervous System Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.